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A B S T R A C T
African swine fever is a highly contagious, often fatal disease of swine for which there is no vaccine or other
curative treatment. The macrophage marker, CD163, is a putative receptor for African swine fever virus (ASFV).
Pigs possessing a complete knockout of CD163 on macrophages were inoculated with Georgia 2007/1, a
genotype 2 isolate. Knockout and wild type pen mates became infected and showed no diﬀerences in clinical
signs, mortality, pathology or viremia. There was also no diﬀerence following in vitro infection of macrophages.
The results do not rule out the possibility that other ASFV strains utilize CD163, but demonstrate that CD163 is
not necessary for infection with the Georgia 2007/1 isolate. This work rules out a signiﬁcant role for CD163 in
ASFV infection and creates opportunities to focus on alternative receptors and entry mechanisms.
1. Introduction
African swine fever virus (ASFV) is a large enveloped double-
stranded DNA virus and the single member of the family Asfarviridae.
The ASFV genome ranges in size from 170 to 193+ kbp, and encodes
150–167 genes (Chapman et al., 2008; de Villiers et al., 2010).
Currently, 23 ASFV genotypes have been identiﬁed based on partial
sequencing of the gene encoding the major capsid protein p72
(Achenbach et al., 2016). ASFV is endemic throughout Sub-Saharan
Africa and the island of Sardinia, but in 2007, the virus produced
outbreaks in the Republic of Georgia, followed by entry of the virus into
the Russian Federation and Eastern Europe (Costard et al., 2013;
Rowlands et al., 2008). The Georgia 2007/1 isolate, a highly virulent
genotype 2 virus, is of great concern to the global swine industry
(Rowlands et al., 2008; Chapman et al., 2011).
ASFV is maintained in nature through the interactions between
African wild pigs (Phacochoerus aethiopicus, Potamochoerus sp.) and
soft ticks of the genus Ornithodoros (Costard et al., 2013). In these
hosts the virus causes a non-clinical, persistent infection. However,
infection of domestic or wild pigs of the species Sus scrofa results in a
febrile illness and widespread systemic hemorrhage that typically
results in death within days (Blome et al., 2013). Isolates can be
divided into high, moderate and low virulence categories, each
associated with a range of clinical and pathological presentations
(Blome et al., 2013; Galindo-Cardiel et al., 2013). Highly virulent
strains can cause acute and hyperacute infections that result in 100%
mortality. Death as a result of hyperacute infection can occur within 2–
4 days, often before the onset of clinical symptoms other than fever.
Infections with low to moderate virulent viruses are associated with
clinical symptoms, and death occurs between 12 and 20 days in 30–
60% of pigs; but mild or unapparent clinical signs with no mortality
may also be observed.
The principal targets for ASFV include cells of the monocyte/
macrophage lineage, and cells of later maturation stages are preferen-
tially infected. Early in vitro studies identiﬁed a receptor-mediated
mechanism for ASFV entry using Vero cell adapted virus. Those studies
employed metabolic inhibitor drugs to block speciﬁc components of
endocytosis and found ASFV infection was reduced (Alcami et al.,
1989a; Valdeira and Geraldes, 1985). Moreover, the binding of ASFV to
the surface of Vero cells was saturable, indicating that there were
speciﬁc receptors being competitively bound by the virus (Alcami et al.,
1989b). These results were replicated in primary macrophages (Alcami
et al., 1990; Galindo et al., 2015). More recent studies have shown that
clathrin-mediated, dynamin dependent endocytosis is a primary path-
way for ASFV entry (Galindo et al., 2015; Hernaez and Alonso, 2010;
Cuesta-Geijo et al., 2012). Despite the broad body of literature in
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support of a receptor-mediated entry mechanism, little work has been
done to identify receptors for ASFV.
The cell tropism of ASFV suggests that a macrophage-speciﬁc
receptor is required for infection. CD163 is a surface marker primarily
expressed on mature tissue macrophages (Pulford et al., 1992), and it
was previously identiﬁed as a receptor for ASFV (Sanchez-Torres et al.,
2003). This conclusion was based on the observation that infected
macrophages possess a mature CD163-positive phenotype, combined
with the capacity of anti-CD163 monoclonal antibodies to block
infection of primary alveolar macrophages in culture (Sanchez-Torres
et al., 2003). Furthermore, the location of epitopes on the N-terminal
end of CD163 recognized by the virus-neutralizing monoclonal anti-
body, 2A10, identiﬁed scavenger receptor cysteine-rich (SRCR) do-
mains 1–3 as the region on CD163 recognized by the virus (Van Gorp
et al., 2010). However, non-permissive cells transfected with a CD163
plasmid remained refractory to infection (Lithgow et al., 2014). One
conclusion from those studies was that CD163 may be necessary but
not suﬃcient for infection, suggesting that other macrophage surface
proteins, such as CD45 and MHC II, may participate in the infection
process (Lithgow et al., 2014).
Another macrophage-tropic virus that utilizes CD163 for infection
is porcine reproductive and respiratory syndrome virus (PRRSV).
Recently, we demonstrated that genetically edited pigs lacking CD163
are non-permissive for PRRSV infection (Whitworth et al., 2016). The
current study tests the hypothesis that CD163 plays an important role
in ASFV infection by infecting the same line of CD163 knockout (KO)
pigs along with wild type (WT) pen mates with the Georgia 2007/1
ASFV isolate, and evaluating outcomes in clinical disease, mortality
and infection of macrophages.
2. Materials and methods
2.1. Ethical statement
Experiments involving animals and virus were performed in
accordance with the Federation of Animal Science Societies Guide for
the Care and Use of Agricultural Animals in Research and Teaching,
the United States Department of Agriculture Animal Welfare Act and
Animal Welfare Regulations, and were approved by the Kansas State
University and University of Missouri Institutional Animal Care and
Use Committees and Institutional Biosafety Committees. Animals were
humanely euthanized by pentobarbital overdose following the
American Veterinary Medical Association guidelines for the euthanasia
of animals, and all eﬀorts were made to minimize suﬀering.
2.2. Virus
The ASFV Georgia 2007/1 isolate (Rowlands et al., 2008; Chapman
et al., 2011) was kindly provided by Linda Dixon at the Pirbright
Institute, and obtained through the generosity of David Williams at the
Commonwealth Scientiﬁc and Industrial Research Organization's
Australian Animal Health Laboratory. Virus was propagated on
primary cultures of porcine alveolar macrophages (PAMs) collected
by lung lavage from 3 to 5 week old piglets. PAMs were washed with
PBS, re-suspended in freezing medium containing 50% fetal bovine
serum (FBS) plus 10% DMSO, and stored in liquid nitrogen until use.
Prior to infection, PAMs were cultured for 2 days in RPMI-1640 culture
medium (Life Technologies) supplemented with 10% FBS and 1x
antibiotics-antimycotic (Gibco), in a 37 °C 5% CO2 incubator. Red
blood cells (RBCs) used for hemadsorption were isolated from hepar-
inized whole pig blood and washed twice with 0.9% saline solution and
maintained at 4 °C in Alsever's solution (Sigma-Aldrich). Virus in
serum or tissue culture media was quantiﬁed by hemadsorption.
Brieﬂy, PAMs cultured on 96-well plates were incubated with serial
dilutions of sample along with a 1% RBC suspension. Samples were
titrated in duplicate and negative controls included uninfected PAMs
incubated with RBCs. The extent of hemadsorption was determined at
5 days after infection and the log10 of 50% hemadsorption dose
(HAD50) calculated using the Spearman-Karber method (Hierholzer
and Killington, 1996).
2.3. Gene-edited CD163 knockout pigs
The CD163 KO pigs were produced using the CRISPR/Cas9 system,
an eﬃcient method of introducing biallelic and homozygous mutations
in pigs, as described previously (Whitworth et al., 2016, 2014). In brief,
founder male and female pigs are produced by two CRISPR/Cas9
techniques. Both utilize the same guide RNA (gRNA) sequence and
human optimized Staphylococcus pyogenes Cas9 endonuclease to
target exon 7 of the CD163 gene. One technique involves transfection
of swine-harvested ﬁbroblasts with the gRNA and Cas9 expressed via
the commercially available pX330 vector. The nucleus from the
transfected ﬁbroblast is transferred to commercially harvested oocytes
via somatic cell nuclear transfer (SCNT) and the reconstructed oocyte
is then in vitro fertilized (IVF). The IVF embryo is then transferred to a
surrogate sow for gestation. Alternatively, unmodiﬁed embryos can
undergo IVF and are then cultured until they become zygotes. The
zygotes are directly injected with messenger RNAs coding for the gRNA
and Cas9 sequences. The modiﬁed zygotes are then transferred on day
6 post-standing estrus into a surrogate sow. The resulting founder
males and females created by either procedures, are bred to produce
oﬀspring that are either wild type (WT), full CD163 knockouts (CD163
-/-), or partial knockouts where only one allele of the CD163 gene is
modiﬁed. For this study, only full knockouts are described and are
referred to as CD163 KO.
2.4. Animal infection and monitoring
Infection studies were performed at the biosafety level 3 (BSL3) and
BSL3-Ag biocontainment facilities at the Kansas State University
Biosecurity Research Institute. Five-week-old CD163 WT (n=10) and
KO (n=6) Large White x Landrace pigs were housed in a single room
and acclimated for four days prior to infection. Ear-tags were randomly
assigned so that caretakers and researchers were blind as to the genetic
identity of the individual pigs. Pigs were infected with 104 HAD50 of
ASFV Georgia 2007/1 via intramuscular injection (IM) in the right
hamstring muscle group. Clinical signs and rectal temperatures were
monitored twice daily. Blood samples were collected on day 0 and 3
post-infection (PI) via jugular venipuncture. At the termination of the
study, three pigs from each CD163 genotype were selected for
necropsy. Following a gross examination, tissue samples collected from
lungs, spleen, tonsils, and inguinal or mesenteric lymph nodes were
placed in 10% PBS-buﬀered formalin. Slide-mounted hematoxylin and
eosin (H &E) stained thin sections were evaluated by a board-certiﬁed
pathologist in the Kansas State Veterinary Diagnostic Laboratory. The
pathologist was blind as to the CD163 genotype of the pigs.
2.5. Infection of PAMs and measurement of CD169 and CD163
expression
Primary cultures of PAMs were collected by lung lavage from WT
and CD163 KO pigs and stored as described above until further use.
PAMs were cultured for 2 days, then inoculated in duplicate with ten-
fold serial dilutions of the Georgia 2007/1 virus and a 1% RBC
suspension. End-point virus titration was determined by hemadsorp-
tion as described above.
Aliquots of PAMs from the same pigs used in the infection
experiments were subjected to surface staining for ﬂow cytometry
analysis. PAMs were washed with PBS and blocked with 5% mouse/5%
rat serum in PBS for 15 min, then incubated for 30 min at 4 °C with
phycoerythrin (PE)-CD163 and ﬂuorescein isothiocyanate (FITC)-
CD169 conjugated antibodies (AbD Serotec; MCA2311PE and
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MCA2316F). Labeled isotype controls were included in each experi-
ment (AbD Serotec: MCA928PE, MCA928F). Cells were washed and
ﬁxed for 15 min at 4 °C with BD Cytoﬁx solution (BD Biosciences) and
analyzed on a BD LSR Fortessa ﬂow cytometer (BD Biosciences) with
BD FACSDiva 8.0.1 software (BD Biosciences). A total of 10,000 events
were collected for analysis.
3. Results
3.1. Clinical signs
After infection, the overall attitude of all pigs quickly declined from
bright, alert and responsive on day 0, to depressed by day 3. One WT
pig displayed cyanosis of the left ear on day 3; however, no other
outward clinical signs were apparent. As shown in Fig. 1, mean
temperatures increased from 39.5 °C on day 1 and peaked at 41.0 °C
on day 3 for both genotypes. There was no statistically signiﬁcant
diﬀerence between the two CD163 genotypes on any day post infection;
however, there was signiﬁcant diﬀerence between the means of base-
line temperatures at 1 DPI and peak temperatures at 3 DPI (p <
0.0001). On days 2 and 3 after infection, all pigs were treated with the
nonsteroidal anti-inﬂammatory drug (NSAID), ﬂunixin meglumine
(Banamine, 50 mg/mL; Merck Animal Health). The study was termi-
nated on day 4 due to the appearance of pyrexia, anorexia, dehydration,
and the failure of pigs to respond to NSAID treatment. Overall, there
was no observable diﬀerence in clinical signs between the CD163 WT
and KO pigs. Acute fever and unapparent clinical symptoms are
consistent with hyperacute ASFV infection (Blome et al., 2013;
Galindo-Cardiel et al., 2013).
3.2. Pathology
At termination of the study, three pigs from each CD163 genotype
group were randomly selected for necropsy. Anatomic pathology
results showed moderate to severe hemorrhagic congestion and
necrosis of the lungs, spleen, and inguinal and mesenteric lymph
nodes. The lungs appeared grossly edematous. At the microscopic level,
acute edema was observed in ﬁve of the six pigs; one WT pig displayed
mild hemorrhage with no edema. Multifocal lymphoid necrosis in the
white and red pulp were present in the spleen of all pigs. Lymph node
samples from ﬁve of the six pigs exhibited a multifocal necrosis, with
one WT pig showing no signiﬁcant microscopic lesions. Tonsils were
mostly within normal limits, with only one WT pig exhibiting widely
scattered multifocal necrosis. The results showed that CD163 KO and
WT pigs exhibited signs consistent with hyperacute ASFV infection,
typical of what has been reported in the literature for infection with the
Georgia 2007/1 isolate (Blome et al., 2013; Galindo-Cardiel et al.,
2013).
3.3. Viremia
Viremia was measured in sera collected from all pigs at 3 days after
infection. Virus levels ranged from 1.6×104 to 1.6×107 HAD50/mL in
the group of WT pigs, and 5×104 to 1.6×107 HAD50/mL for the CD163
KO pigs (see Fig. 2). There was no statistical diﬀerence in the levels of
viremia between the WT and CD163 KO pigs.
3.4. Infection of PAMs
Previous work that identiﬁed a role for CD163 in ASFV infection
was performed on primary macrophage cultures. Those studies demon-
strated that PAMs (~76%) are more permissive for ASFV infection in
vitro compared to blood monocytes or bone marrow precursor cells,
and infection positively correlates with CD163 expression (Sanchez-
Torres et al., 2003). In the current study, permissiveness of PAMs from
WT and CD163 KO pigs was evaluated by comparing the titration end-
points after in vitro inoculation with the Georgia 2007/1 isolate. As
shown in Fig. 3, similar end-point infectious titers were achieved for
macrophages from one representative WT and three CD163 KO pigs.
PAMs from these same pigs were assessed by ﬂow cytometry for surface
expression of the macrophage markers CD163 and CD169. Relatively
high levels of surface CD163 was expressed on WT PAMs, while
staining of CD163 KO PAMs was comparable to the negative isotype
control, shown in Fig. 3. Both CD163 genotypes of PAMs expressed
similar levels of another alveolar macrophage marker, CD169.
4. Discussion
The role of CD163 in ASFV infection is controversial. Previous work
by Sanchez-Torres et al. (2003) strongly supported the requirement of
CD163 as a receptor for ASFV on macrophages. However, subsequent
work failed to recover permissiveness of CD163-negative cell lines after
transfection with a CD163 plasmid (Lithgow et al., 2014). Nonetheless,
those negative results do not rule out CD163 as a necessary co-
receptor. CD163 alone may not be suﬃcient for infection but require
the cooperation of additional macrophage-speciﬁc proteins. The results
from the current study clearly demonstrate that CD163 is not essential
for infection of PAMs with the Georgia isolate. While this study and
previous work both assessed infection of PAMs, the strains of ASFV
used diﬀer. This work does not entirely rule out the receptor require-
ments of other ASFV isolates.
In the absence of CD163, it is plausible that other surface markers
may be upregulated to compensate; however, we saw no evidence to
Fig. 1. Rectal temperatures of wild type (WT) and knockout (KO) pigs infected with
Georgia 2007/1. Means with standard deviations are shown. A one-way ANOVA analysis
showed no signiﬁcant diﬀerence between temperatures of WT and KO pigs on any day (p
> 0.96). The analysis did show a signiﬁcant increase in mean temperatures from day 1–3
for both WT and KO groups (p < 0.0001). Fig. 2. Viremia of wild type (WT) and knockout (KO) pigs infected with Georgia 2007/1.
Virus titers of day 3 post infection serum samples were determined by 50% hemadsorp-
tion (HAD50) on alveolar macrophages. Closed and open circles represent individual pigs
from each group with the means and standard deviations indicated. A paired T-test
showed no signiﬁcant diﬀerence between virus titers of WT and KO pigs (p > 0.93).
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support this. Here we used the alveolar macrophage-speciﬁc surface
protein, CD169, as a control. CD169 and CD163 are normally
expressed at similar levels on the surface of porcine PAMs
(Whitworth et al., 2016). Based on results from this study and previous
characterization of PAMs from CD163 modiﬁed pigs by our lab
(Whitworth et al., 2016), we found that surface expression of CD169
remains similar to WT PAMs in the absence of CD163. Other
macrophage surface markers, including CD14, MHC II and CD172,
were also found to be expressed at similar levels for both WT and
CD163 KO genotypes (Whitworth et al., 2016). However, this does not
exclude changes in expression of other macrophage surface proteins
which were not evaluated.
While there is support for receptor-dependent entry mechanisms,
such as clathrin-mediated endocytosis (CME) (Galindo et al., 2015;
Hernaez and Alonso, 2010), there is also evidence that ASFV may
exploit non-receptor mechanisms, such as macropinocytosis (Sanchez
et al., 2012; Hernaez et al., 2016). Macropinocytosis is the non-
selective, actin-dependent uptake of molecules (Kerr and Teasdale,
2009), and is utilized by several large DNA viruses, including vaccinia
virus, herpes simplex virus 1, and adenovirus 3, and others (Mercer
and Helenius, 2009). Recently, Hernaez et al. (2016) demonstrated
that both pathways, CME and macropinocytosis, are utilized by ASFV
for entry into permissive cells. That study incorporated ﬂuorescence
and transmission electron microscopy (TEM) to document the early
events during infection of PAMs. Puriﬁed labeled virions were shown to
co-localize with dextran, a macropinocytosis marker, as well as
transferrin, a marker for CME. Sixty-eight percent of virions co-
localized with dextran. Further support comes from TEM studies,
which show virus particles in macropinocytic-like processes; a small
percentage of virions were also found in dense-membrane invagina-
tions typical of clathrin-coated pits. Chemical inhibitors of either CME
(Chlorpromazine, pitstop 2 and dynasore) or macropinocytosis (EIPA,
IPA-3 and cytochalasin D) inhibited ASFV entry into PAMs (Hernaez
et al., 2016). Nonetheless, if ASFV utilizes macropinocytosis as a non-
speciﬁc mechanism for entry, then other intracellular macrophage-
speciﬁc interactions must be involved which deﬁne ASFV tropism. The
mechanism of entry for ASFV in the KO PAMs is currently unknown
and a topic for further study.
Even though the current study rules out the requirement of CD163
for ASFV infection, the absence of CD163 in the KO pigs could aﬀect
the host response to infection. For example, the expression of CD163 is
linked to a subpopulation of macrophages described as anti-inﬂamma-
tory. Both CD163 expression and the polarization of macrophages to an
M2 phenotype are induced by interleukin (IL)-6, IL-10 and glucocorti-
Fig. 3. Infection of wild type (WT) and CD163 knockout (KO) PAMs with ASFV Georgia 2007/1. Flow cytometry for CD163 and CD169 surface expression on PAMs of representative
animals are shown. Percentage of labeled cells is expressed on the Y-axis and ﬂuorescence intensity is indicated by the X-axis. Red and green peaks show cells labeled with CD163 and
CD169 antibodies, respectively; grey peaks represent non-speciﬁc background ﬂuorescence of the corresponding antibody isotype. HAD50 titrations of Georgia 2007/1 on WT and
CD163 KO PAMs are shown on the right. ASFV=African swine fever virus; PAMs=pulmonary alveolar macrophages; HAD50=50% hemadsorption dose. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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coids (Hogger et al., 1998; Buechler et al., 2000; Gordon, 2003). M2
regulatory macrophages are upregulated in response to both innate and
adaptive immune responses, and appear to play an immunosuppressive
role by producing high levels of the anti-inﬂammatory cytokine IL-10
(Mosser and Edwards, 2008). CD163 is a component of a haptoglobin/
hemoglobin scavenging complex which reduces inﬂammation that
results from oxidative stress caused by excess circulating heme
(Kristiansen et al., 2001). Furthermore, heme degradation products
produced by CD163-positive macrophages act as potent anti-inﬂam-
matory compounds (Jeney et al., 2002; Soares and Bach, 2009).
Upregulation of soluble CD163 is associated with inﬂammatory and
hemorrhagic diseases in patients with virus infections (Buechler et al.,
2013; Wang et al., 2014). One possibility is that the soluble form of
CD163 may act like an anti-inﬂammatory cytokine to downregulate
inﬂammation and T-cell activation as demonstrated in vitro (Frings
et al., 2002). Thus, in the absence of CD163, it would be predicted that
the presence of a hemorrhagic disease would enhance the inﬂammatory
response in the CD163 KO pigs. However, there appeared to be no
diﬀerences in the clinical outcome and histopathology between CD163
KO and wild type pigs.
5. Conclusion
Taken together, the results of this study indicate that CD163 is not
critical for ASFV infection of PAMs or progression of the disease in
pigs. Nonetheless, because ASFV replication is primarily restricted to
macrophages, it is clear that other macrophage-associated proteins are
involved in ASFV tropism and may represent important targets for
genetic modiﬁcation.
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